We are live on ! Find out more
IIP

Intermede Investment Partners Portfolio holdings

AUM $2.16B
1-Year Est. Return 18.47%
This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+18.47%
3 Year Est. Return
+69.55%
5 Year Est. Return
+72.34%
10 Year Est. Return
+364.13%
AUM
$1.69B
AUM Growth
+$80.8M
Cap. Flow
-$11.1M
Cap. Flow %
-0.66%
Top 10 Hldgs %
52.24%
Holding
26
New
1
Increased
3
Reduced
20
Closed
1

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$71.8M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$7.51M
3
TSM icon
TSMC
TSM
+$7.13M
4
BABA icon
Alibaba
BABA
+$6.12M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$62.3M
2
CL icon
Colgate-Palmolive
CL
+$10.7M
3
ZTS icon
Zoetis
ZTS
+$9.46M
4
ECL icon
Ecolab
ECL
+$4.73M
5
MA icon
Mastercard
MA
+$1.68M

Sector Composition

Rank Sector Weight
1 Financials 22.26%
2 Healthcare 19.28%
3 Communication Services 19.19%
4 Technology 17.41%
5 Industrials 6.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
26
DELISTED
Allergan plc
AGN
– –
-425,529
Closed -$62.3M
1
2

Similar funds

MA
Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
MIAS
Mason Investment Advisory Services Reston, Virginia $2.17B AUM 28.39% 1-Year Est. Return
MMLI
Massachusetts Mutual Life Insurance Springfield, Massachusetts $2.17B AUM 48.68% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
ET
Entropy Technologies New York $2.17B AUM 21.46% 1-Year Est. Return
NAAA
New Age Alpha Advisors Rye, New York $2.15B AUM 27.2% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.17B AUM 11.2% 1-Year Est. Return

Intermede Investment Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Intermede Investment Partners held 26 positions worth $1.69B, up 5% from $1.61B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Intermede Investment Partners's Q2 2019 filing shows 1 new, 3 increased, 20 reduced and 1 closed positions. Its largest new stake was Becton Dickinson: 309,192 shares worth $76M. The largest sale was Allergan plc, an estimated $62.3M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, up from 22% a quarter earlier, followed by Healthcare and Communication Services.

  • Intermede Investment Partners's largest Q2 2019 buy was Becton Dickinson: 309,192 shares worth $76M.
  • Intermede Investment Partners added most to Bio-Rad Laboratories Class A in Q2 2019, an estimated $7.51M increase.
  • Intermede Investment Partners's biggest Q2 2019 reduction was Colgate-Palmolive, cutting an estimated $10.7M.
  • Intermede Investment Partners fully exited Allergan plc in Q2 2019, selling an estimated $62.3M.
  • Intermede Investment Partners's ten largest holdings make up 52% of its $1.69B portfolio in Q2 2019.
  • Intermede Investment Partners opened 1 new position and closed 1 in Q2 2019.
  • Intermede Investment Partners's portfolio value rose 5% quarter-over-quarter to $1.69B.

Based on Intermede Investment Partners's 13F filing for Q2 2019, filed 30 Jul 2019.